ChiCTR2600126615 版本V1.0 版本创建时间2026/06/12 11:16:19 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600126615 

最近更新日期:

Date of Last Refreshed on:

2026-06-12 11:16:02 

注册时间:

Date of Registration:

2026-06-12 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于胸部非增强CT的偶发性肺动脉栓塞人工智能筛查模型多中心前瞻性静默观察研究

Public title:

A Multicenter Prospective Silent Observation Study of an Artificial Intelligence Screening Model for Incidental Pulmonary Embolism on Non-contrast Chest CT

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于胸部非增强CT的偶发性肺动脉栓塞人工智能筛查模型多中心前瞻性静默观察研究

Scientific title:

A Multicenter Prospective Silent Observation Study of an Artificial Intelligence Screening Model for Incidental Pulmonary Embolism on Non-contrast Chest CT

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

胡毓健 

研究负责人:

张鸿坤 

Applicant:

Yujian Hu 

Study leader:

Hongkun Zhang 

申请注册联系人电话:

Applicant telephone:

+86 188 8892 6482

研究负责人电话:

Study leader's
telephone:

+86 135 8823 0962

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

huyujian@zju.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

1198050@zju.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

杭州市上城区庆春路79号

研究负责人通讯地址:

杭州市上城区庆春路79号

Applicant address:

79 Qingchun Rd., Shangcheng District, Hangzhou

Study leader's address:

79 Qingchun Rd., Shangcheng District, Hangzhou

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

浙江大学医学院附属第一医院

Applicant's institution:

The First Affiliated Hospital of Zhejiang University School of Medicine

研究负责人所在单位:

浙江大学医学院附属第一医院

Affiliation of the Leader:

The First Affiliated Hospital of Zhejiang University School of Medicine

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

扫描浙大一院伦审2026研第0672号-快

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

浙江大学医学院附属第一医院IIT伦理审查委员会

Name of the ethic committee:

Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2026-06-08 00:00:00

伦理委员会联系人:

殷琳

Contact Name of the ethic committee:

Lin Yin

伦理委员会联系地址:

杭州市上城区庆春路79号

Contact Address of the ethic committee:

79 Qingchun Rd., Shangcheng District, Hangzhou

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 571 8723 1830

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

浙江大学医学院附属第一医院

Primary sponsor:

The First Affiliated Hospital of Zhejiang University School of Medicine

研究实施负责(组长)单位地址:

杭州市上城区庆春路79号

Primary sponsor's address:

79 Qingchun Rd., Shangcheng District, Hangzhou

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

Country:

China

Province:

Zhejiang

City:

单位(医院):

浙江大学医学院附属第一医院

具体地址:

杭州市上城区庆春路79号

Institution
hospital:

The First Affiliated Hospital of Zhejiang University School of Medicine

Address:

79 Qingchun Rd., Shangcheng District, Hangzhou

经费或物资来源:

浙江省“尖兵”研发攻关计划(2024C03023)

Source(s) of funding:

Technical Innovation key project of Zhejiang Province (grant no. 2024C03023)

研究疾病:

肺动脉栓塞  

Target disease:

pulmonary embolism

研究疾病代码:

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

诊断试验诊断准确性 

Study design:

Diagnostic test for accuracy 

研究目的:

本研究旨在真实临床影像工作流中前瞻性静默运行已构建并锁定版本的人工智能模型,评价其在常规胸部非增强CT检查中对偶发性肺动脉栓塞的阳性提示质量、告警负担、潜在临床可操作性及系统运行稳定性。  

Objectives of Study:

This study aims to prospectively and silently run a built and version-locked artificial intelligence model within a real-world clinical imaging workflow, and to evaluate its performance in terms of the quality of positive alerts for incidental pulmonary embolism on routine non-contrast chest CT examinations, alert burden, potential clinical actionability, and system operational stability.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄 ≥18 岁; 2.在研究期间内于参与中心完成常规胸部非增强CT检查; 3.经锁定版本人工智能模型判定为阳性

Inclusion criteria

1.Age >=18 years. 2. Underwent a routine non-contrast chest CT examination at a participating center during the study period. 3. Judged as positive by the version?locked artificial intelligence model.

排除标准:

1.所纳入检查前已明确诊断肺动脉栓塞,且本次检查不属于新的机会性筛查场景; 2.该次检查以怀疑肺动脉栓塞为主要目的进行,或已明确进入肺动脉栓塞相关确证性检查路径; 3.基准检查影像存在严重运动伪影、金属伪影、数据损坏或扫描范围明显不足,无法进行可靠人工智能推理; 4.影像或临床资料严重缺失,无法完成基本核验流程。

Exclusion criteria:

1. A definite diagnosis of pulmonary embolism was made prior to the enrolled examination, and the current examination does not represent a new opportunistic screening scenario. 2. The examination was performed primarily with suspected pulmonary embolism as the main purpose, or the patient had already been clearly entered into a confirmatory diagnostic pathway for pulmonary embolism. 3. The baseline examination images have severe motion artifacts, metal artifacts, data corruption, or clearly insufficient scan coverage, rendering reliable artificial intelligence inference impossible. 4. Severe lack of imaging or clinical data prevents completion of the basic verification process.

研究实施时间:

Study execute time:

From 2026-06-15 00:00:00 To 2026-10-15 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-06-15 00:00:00 To 2026-10-12 00:00:00

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

1.72小时内的确证性影像检查结果(包括CTPA、V/Q扫描、肺动脉MRA或技术质量足以评价肺动脉的增强CT检查及其结果) 2.专家复核结果(专家组结合基线胸部非增强CT影像、AI提示区域、原始放射报告、72小时内临床经过、相关症状随访及后续诊疗信息进行综合复核)

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

1.Confirmatory imaging examination results within 72 hours (including CTPA, V/Q scan, pulmonary MRA, or contrast?enhanced CT of sufficient technical quality to evaluate the pulmonary arteries, and their findings). 2. Expert adjudication results (comprehensive review by an expert panel based on the baseline non?contrast chest CT images, AI?highlighted regions, original radiology report, clinical course within 72 hours, relevant symptom follow?up, and subsequent diagnostic and treatment information).

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

AI阳性病例的整体阳性预测值

Index test:

Overall positive predictive value of AI-positive cases

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

已接受常规胸部非增强CT检查、未明确诊断肺动脉栓塞且AI整体预测值阳性的患者

例数:

Sample size:

359

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

Patients who undergo routine non-contrast chest CT examination, have no definite diagnosis of pulmonary embolism, and are overall AI?positive predicted

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

例数:

Sample size:

0

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

None

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China

Province:

Zhejiang Province

City:

单位(医院):

浙江大学医学院附属第一医院 

单位级别:

三甲 

Institution
hospital:

The First Affiliated Hospital of Zhejiang University School of Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

绍兴市中心医院 

单位级别:

三乙 

Institution
hospital:

Shaoxing Central Hospital

Level of the institution:

Tertiary B

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

衢州市人民医院 

单位级别:

三甲 

Institution
hospital:

Quzhou People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

衢州市柯城区人民医院 

单位级别:

二甲 

Institution
hospital:

People's Hospital of Kecheng District, Quzhou City

Level of the institution:

Secondary A

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

安吉县人民医院 

单位级别:

二甲 

Institution
hospital:

Anji People's Hospital

Level of the institution:

Secondary A

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

浙江医院 

单位级别:

三甲 

Institution
hospital:

Zhejiang Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

温州市中心医院 

单位级别:

三甲 

Institution
hospital:

Wenzhou Central Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

山东省立医院 

单位级别:

三甲 

Institution
hospital:

Shandong Provincial Hospital Affiliated to Shandong First Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

AI阳性病例的整体阳性预测值

指标类型:

主要指标

Outcome:

Overall positive predictive value of AI?positive cases

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

影像学确证的阳性预测值

指标类型:

次要指标

Outcome:

Imaging-confirmed positive predictive value

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

专家复核支持的阳性预测值

指标类型:

次要指标

Outcome:

Expert-adjudicated positive predictive value

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不同临床场景和高危亚组中的PPV

指标类型:

次要指标

Outcome:

Positive predictive value (PPV) in different clinical scenarios and high-risk subgroups

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不同中心及不同扫描条件下的模型表现

指标类型:

次要指标

Outcome:

Model performance across different centers and scanning conditions

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用病例记录表采集数据,使用EDC管理数据

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form and EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2026-06-12 11:16:02